NAMS - NewAmsterdam Pharma Co N.V Common Stock

NewAmsterdam Pharma Co N.V (NAMS)

NGM · Common · CUSIP N62509109

Last Price•••.••

Current Yield•.••%

Yield to Call•.••%

Yield to Worst•.••%

Free registration unlocks the quote, yield calculations, price chart and full fundamentals for NAMS and every other security on QuantumOnline.

Overview Financials 🔒 Earnings 🔒 Dividends 🔒 Analysts 🔒 Ownership 🔒 ESG 🔒 Technicals 🔒

🔒

Price chart and 15 days of daily prices

Candlestick chart with moving averages, Bollinger bands and MACD. Register free to view.

Security Profile

Security Type: Common Stock
CUSIP: N62509109
Market Cap: Large Cap

Links: Home Page Investor Relations News

Business: NewAmsterdam Pharma Co N.V s a clinical-stage biopharmaceutical company. NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C lowering therapy to be used as an adjunct to maximally tolerated statin therapy for high-risk cardiovascular disease (“CVD”) patients.

Company Contact

CEO: Michael Davidson
CFO: Ian Somaiya
Investor Relations: Hannah Deresiewicz, Stern IR · 212-362-1200 · hannah.deresiewicz@sternir.com
Email Form: Contact Form »
SEC EDGAR Filings: View filings »